Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Brain Neoplasms 3Paraganglioma, Extra-Adrenal 2Neoplasms 2Glioma 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Meningeal Carcinomatosis 1Melanoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Medullary 1Biliary Tract Neoplasms 1

Interventions

3-Iodobenzylguanidine 13lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 4Temozolomide 4Specimen Handling 4anlotinib 3Magnetic Resonance Spectroscopy 3Everolimus 3pegfilgrastim 2olaparib 2cabozantinib 2belzutifan 2Radiotherapy 2Phenoxybenzamine 2Nivolumab 2Granulocyte Colony-Stimulating Factor 2Fluorodeoxyglucose F18 2Biopsy 2Axitinib 23-fluorobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1tipifarnib 1temsirolimus 1talazoparib 1spartalizumab 1pentetreotide 1penpulimab 1pembrolizumab 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pheochromocytoma × lenvatinib × CNS × Clear all
NCT03008369 2024-02-20

Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery

Mayo Clinic

Phase 2 Completed
3 enrolled 9 charts
CNSEndocrine

Paraganglioma, Extra-Adrenal, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡